Characterization of a lympho-inhibitory peptide produced by Mycoplasma bovis

Biochemical and Biophysical Research Communications

Volumn 315, Issue 2, 2004, Pages 336-341

  Vanden Bush, Tony J ^a   Rosenbusch, Ricardo F ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

Immunosuppression; Lymphocyte; Mycoplasma bovis; PBMC; Peptide

Indexed keywords

CONCANAVALIN A; IMMUNOSUPPRESSIVE AGENT; LYMPHO INHIBITORY PEPTIDE; MEMBRANE PROTEIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VARIABLE SURFACE PROTEIN L;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GEL PERMEATION CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MYCOPLASMA; MYCOPLASMA BOVIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SUPERNATANT;

BOVINAE; MYCOPLASMA; MYCOPLASMA BOVIS;

EID: 0842332227     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.01.063     Document Type: Article

References (42)

1. Razin S., Yogev D., Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol. Mol. Biol. Rev. 62:1998;1094-1156.
2. Razin S. Mycoplasmas: the smallest pathogenic procaryotes. Isr. J. Med. Sci. 17:1981;510-515.
3. Nicolet J. Animal mycoplasmoses: a general introduction. Rev. Sci. Tech. 15:1996;1233-1240.
4. Lysnyansky I., Rosengarten R., Yogev D. Phenotypic switching of variable surface lipoproteins in Mycoplasma bovis involves high-frequency chromosomal rearrangements. J. Bacteriol. 178:1996;5395-5401.
5. Sachse K., Helbig J.H., Lysnyansky I., Grajetzki C., Muller W., Jacobs E., Yogev D. Epitope mapping of immunogenic and adhesive structures in repetitive domains of Mycoplasma bovis variable surface lipoproteins. Infect. Immun. 68:2000;680-687.
6. Rosengarten R., Wise K.S. Phenotypic switching in mycoplasmas: phase variation of diverse surface lipoproteins. Science. 247:1990;315-318.
7. Thomas C.B., Van Ess P., Wolfgram L.J., Riebe J., Sharp P., Schultz R.D. Adherence to bovine neutrophils and suppression of neutrophil chemiluminescence by Mycoplasma bovis. Vet. Immunol. Immunopathol. 27:1991;365-381.
8. Thomas C.B., Mettler J., Sharp P., Jensen-Kostenbader J., Schultz R.D. Mycoplasma bovis suppression of bovine lymphocyte response to phytohemagglutinin. Vet. Immunol. Immunopathol. 26:1990;143-155.
9. Adegboye D.S. A review of mycoplasma-induced immunosuppression. Br. Vet. J. 134:1978;556-560.
10. Lysnyansky I., Ron Y., Sachse K., Yogev D. Intrachromosomal recombination within the vsp locus of Mycoplasma bovis generates a chimeric variable surface lipoprotein antigen. Infect. Immun. 69:2001;3703-3712.
11. Ron Y., Flitman-Tene R., Dybvig K., Yogev D. Identification and characterization of a site-specific tyrosine recombinase within the variable loci of Mycoplasma bovis, Mycoplasma pulmonis and Mycoplasma agalactiae. Gene. 292:2002;205-211.
12. Lysnyansky I., Ron Y., Yogev D. Juxtaposition of an active promoter to vsp genes via site-specific DNA inversions generates antigenic variation in Mycoplasma bovis. J. Bacteriol. 183:2001;5698-5708.
13. Lysnyansky I., Sachse K., Rosenbusch R., Levisohn S., Yogev D. The vsp locus of Mycoplasma bovis: gene organization and structural features. J. Bacteriol. 181:1999;5734-5741.
14. Romero-Rojas A., Reyes-Esparza J., Estrada-Parra S., Hadden J.W. Immunomodulatory properties of Mycoplasma pulmonis. III. Lymphocyte stimulation and cytokine production by Mycoplasma pulmonis products. Int. Immunopharmacol. 1:2001;1699-1707.
15. Teh H.S., Ho M., Williams L.D. Suppression of cytotoxic responses by a supernatant factor derived from Mycoplasma hyorhinis-infected mammalian cell lines. Infect. Immun. 56:1988;197-203.
16. Tsunekawa H., Takagi E., Kishimoto H., Shimokata K. Depressed cellular immunity in Mycoplasma pneumoniae pneumonia. Eur. J. Respir. Dis. 70:1987;293-299.
17. Pfutzner H., Sachse K. Mycoplasma bovis as an agent of mastitis, pneumonia, arthritis and genital disorders in cattle. Rev. Sci. Tech. 15:1996;1477-1494.
18. Sachse K., Pfutzner H., Heller M., Hanel I. Inhibition of Mycoplasma bovis cytadherence by a monoclonal antibody and various carbohydrate substances. Vet. Microbiol. 36:1993;307-316.
19. Thomas A., Sachse K., Dizier I., Grajetzki C., Farnir F., Mainil J.G., Linden A. Adherence to various host cell lines of Mycoplasma bovis strains differing in pathogenic and cultural features. Vet. Microbiol. 91:2003;101-113.
20. Thomas A., Sachse K., Farnir F., Dizier I., Mainil J., Linden A. Adherence of Mycoplasma bovis to bovine bronchial epithelial cells. Microb. Pathog. 34:2003;141-148.
21. Finch J.M., Howard C.J. Inhibitory effect of Mycoplasma dispar and Mycoplasma bovis on bovine immune responses in vitro. Zentralbl. Bakteriol. Suppl. 20:1990;563-569.
22. Vanden Bush T.J., Rosenbusch R.F. Mycoplasma bovis induces apoptosis of bovine lymphocytes. FEMS Immunol. Med. Microbiol. 32:2002;97-103.
23. Vanden Bush T.J., Rosenbusch R.F. Characterization of the immune response to Mycoplasma bovis lung infection. Vet. Immunol. Immunopathol. 94:2003;23-33.
24. Behrens A., Heller M., Kirchhoff H., Yogev D., Rosengarten R. A family of phase- and size-variant membrane surface lipoprotein antigens (Vsps) of Mycoplasma bovis. Infect. Immun. 62:1994;5075-5084.
25. + channel. J. Biol. Chem. 266:1991;3668-3674.
26. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol. 166:2001;936-944.
27. Gairi M., Romi R., Fernandez I., Rochat H., Martin-Eauclaire M.F., Van Rietschoten J., Pons M., Giralt E. 3D structure of kaliotoxin: is residue 34 a key for channel selectivity? J. Pept. Sci. 3:1997;314-319.
28. Jensen B.S., Odum N., Jorgensen N.K., Christophersen P., Olesen S.P. Inhibition of T cell proliferation by selective block of Ca(2+)-activated K(+) channels. Proc. Natl. Acad. Sci. USA. 96:1999;10917-10921.
29. Koo G.C., Blake J.T., Talento A., Nguyen M., Lin S., Sirotina A., Shah K., Mulvany K., Hora D. Jr., Cunningham P., Wunderler D.L., McManus O.B., Slaughter R., Bugianesi R., Felix J., Garcia M., Williamson J., Kaczorowski G., Sigal N.H., Springer M.S., Feeney W. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. 158:1997;5120-5128.
30. Pennington M.W., Lanigan M.D., Kalman K., Mahnir V.M., Rauer H., McVaugh C.T., Behm D., Donaldson D., Chandy K.G., Kem W.R., Norton R.S. Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin. Biochemistry. 38:1999;14549-14558.
31. Price M., Lee S.C., Deutsch C. Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA. 86:1989;10171-10175.
32. Kalman K., Pennington M.W., Lanigan M.D., Nguyen A., Rauer H., Mahnir V., Paschetto K., Kem W.R., Grissmer S., Gutman G.A., Christian E.P., Cahalan M.D., Norton R.S., Chandy K.G. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J. Biol. Chem. 273:1998;32697-32707.
33. Bontems F., Roumestand C., Gilquin B., Menez A., Toma F. Refined structure of charybdotoxin: common motifs in scorpion toxins and insect defensins. Science. 254:1991;1521-1523.
34. Gilquin B., Racape J., Wrisch A., Visan V., Lecoq A., Grissmer S., Menez A., Gasparini S. Structure of the BgK-Kv1.1 complex based on distance restraints identified by double mutant cycles. Molecular basis for convergent evolution of Kv1 channel blockers. J. Biol. Chem. 277:2002;37406-37413.
35. Betten A., Bylund J., Cristophe T., Boulay F., Romero A., Hellstrand K., Dahlgren C. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. J. Clin. Invest. 108:2001;1221-1228.
36. Cole B.C., Wells D.J. Immunosuppressive properties of the Mycoplasma arthritidis T-cell mitogen in vivo: inhibition of proliferative responses to T-cell mitogens. Infect. Immun. 58:1990;228-236.
37. Dannecker G., Schultz H., Mecheri S., Sappler G., Clarke K., Niethammer D., Hoffmann M.K. Characterization of anergy to the superantigen Staphylococcus enterotoxin B. Immunodeficiency. 4:1993;137-139.
38. + T cells reactivated with superantigen are both more sensitive to FasL-mediated killing and express a higher level of FasL. Cell. Immunol. 179:1997;153-164.
39. + T cells. J. Immunol. 154:1995;6306-6313.
40. Into T., Fujita M., Okusawa T., Hasebe A., Morita M., Shibata K. Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages. Infect. Immun. 70:2002;3586-3591.
41. Into T., Okada K., Inoue N., Yasuda M., Shibata K. Extracellular ATP regulates cell death of lymphocytes and monocytes induced by membrane-bound lipoproteins of Mycoplasma fermentans and Mycoplasma salivarium. Microbiol. Immunol. 46:2002;667-675.
42. Beeton C., Wulff H., Barbaria J., Clot-Faybesse O., Pennington M., Bernard D., Cahalan M.D., Chandy K.G., Beraud E. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. USA. 98:2001;13942-13947.